pharma · COVID-19 · Hepatitis C · AVIR
Atea Pharmaceuticals
Atea Pharmaceuticals clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 225 Franklin St, Suite, 2100, Boston, Massachusetts 02110, US
- Founded
- 2014
- Employees
- 57
- Programs
- 37
- Drugs
- 29
- Patents
- 35
Atea Pharmaceuticals projects
5 ClinicalTrials.gov programs sponsored by Atea Pharmaceuticals.
Atea Pharmaceuticals has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AT-01B-008
Atea Pharmaceuticals
Chronic Hepatitis C Virus (HCV) Infection
1 trial -
Bemnifosbuvir (BEM)
Atea Pharmaceuticals
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)
1 trial -
Bemnifosbuvir-Ruzasvir
Atea Pharmaceuticals
HEPATITIS C VIRUS CHRONIC INFECTION
1 trial -
Bemnifosbuvir-Ruzasvir (BEM/RZR)
Atea Pharmaceuticals
HEPATITIS C VIRUS CHRONIC INFECTION
1 trial -
RO7496998
Atea Pharmaceuticals
COVID-19
1 trial
Frequently asked questions
How many clinical projects does Atea Pharmaceuticals have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.